Synthesis and properties of N,N′-bis(5-aminosalicyl)-L-cystine as a colon-specific deliverer of 5-aminosalicylic acid and cystine

Drug Delivery

Volumn 15, Issue 1, 2008, Pages 37-42

  Kim, Heejung ^a   Kim, Duksoo ^a   Choi, Daekyu ^a   Jeon, Hyunchu ^a   Han, Jungoh ^a   Jung, Yunjin ^a   Kong, Hyesik ^b   Kim, Young Mi ^a  

^a Pusan National University   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 Aminosalicylic Acid; Colon Specific Deliverer; Cysteine; GSH Precursor; Inflammatory Bowel Disaese

Indexed keywords

CYSTINE; MESALAZINE; N,N BIS(5 AMINOSALICYL)CYSTINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; DRUG URINE LEVEL; MALE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RAT; THIN LAYER CHROMATOGRAPHY;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOTRANSFORMATION; CECUM; COLON; CYSTINE; DRUG STABILITY; GASTROINTESTINAL AGENTS; HIPPURATES; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; STOMACH;

EID: 38149133786     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540701828806     Document Type: Article

References (20)

1. Ardite, E., Sans, M., Panes, J., Romero, F. J., Pique, J. M., and Fernandez-Checa, J. C. 2000. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab. Invest. 80:735-744.
2. Aw, T. Y. 2005. Intestinal glutathione: determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility. Toxicol. Appl. Pharmacol. 204:320-328.
3. Bai, J. P., Chang, L. L., and Guo, J. H. 1995. Targeting of peptide and protein drugs to specific sites in the oral route. Crit. Rev. Ther. Drug. Carrier Syst. 12:339-371.
4. Chourasia, M. K., and Jain, S. K. 2003. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Sci. 6:33-66.
5. Crotty, B., and Jewell, D. P. 1992. Drug therapy of ulcerative colitis. Br. J. Clin. Pharmacol. 34:189-198.
6. Grisham, M. B., and Granger, D. N. 1988. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig. Dis. Sci. 33:6S-15S.
7. Jung, Y., Kim, H. H., Kim, H., Kong, H., Choi, B., Yang, Y., and Kim, Y. 2006. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur. J. Pharm. Sci. 28:26-33.
8. Jung, Y. J., Kim, H. H., Kong, H. S., and Kim, Y. M. 2003. Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid. Arch. Pharm. Res. 26:264-269.
9. Jung, Y. J., Lee, J. S., and Kim, Y. M. 2000. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J. Pharm. Sci. 89:594-602.
10. Lofberg, R. 2003. Reviewarticle: medical treatment of mild to moderately active Crohn's disease. Aliment. Pharmacol. Ther. 17 suppl 2:18-22.
11. Mahida, Y. R., Wu, K. C., and Jewell, D. P. 1989. Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. Gut 30:1362-1370.
12. McKenzie, S. J., Baker, M. S., Buffinton, G. D., and Doe, W. F. 1996. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Invest. 98:136-141.
13. Miller, L. T., Watson, W. H., Kirlin, W. G., Ziegler, T. R., and Jones, D. P. 2002. Oxidation of the glutathione/glutathione disulfide redox state is induced by cysteine deficiency in human colon carcinoma HT29 cells. J. Nutr. 132:2303-2306.
14. Novis, B. H., Korzets, Z., Chen, P., and Bernheim, J. 1988. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br. Med. J. (Clin. Res. Ed). 296:1442.
15. Oz, H. S., Chen, T. S., McClain, C. J., and de Villiers, W. J. 2005. Antioxidants as novel therapy in a murine model of colitis. J. Nutr. Biochem. 16:297-304.
16. Peppercorn, M. A., and Goldman, P. 1972. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther. 181:555-562.
17. Sinha, V. R., and Kumria, R. 2001. Colonic drug delivery: prodrug approach. Pharm. Res. 18:557-564.
18. Van den Mooter, G. 2006. Colon drug delivery. Expert. Opin. Drug. Del. 3:111-125.
19. Williams, J. G. 1990. Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment. Ann. R. Coll. Surg. Engl. 72:253-262.
20. Zhou, S. Y., Fleisher, D., Pao, L. H., Li, C., Winward, B., and Zimmermann, E. M. 1999. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab. Dispos. 27:479-485.